Recombinant varicella zoster virus glycoprotein e antigen for herpes zoster

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 15 Dec 2025: Trial started, NCT07293065
  2. 18 Dec 2025: Trial registered, NCT07293065
  3. 20 Mar 2026: Trial registered, NCT07485283
  4. 31 Mar 2026: Trial registered, NCT07502560
  5. 31 Mar 2026: Trial started, NCT07502560
  6. 28 Apr 2026: Trial started, NCT07485283

The trials

NCT07293065: A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)

State
Under way
Phase
Phase 3
People
12,000 planned
Started
15 Dec 2025
Primary completion
31 Dec 2027
Arms
Vaccine Group
Results
None posted
  1. 15 Dec 2025: Trial started
  2. 18 Dec 2025: Trial registered

NCT07485283: Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia

State
Under way
Phase
Phase 4
People
168,460 taking part
Started
28 Apr 2026
Primary completion
Jun 2029
Arms
Recombinant Herpes Zoster Vaccine (Shingrix).
Results
None posted
  1. 20 Mar 2026: Trial registered
  2. 28 Apr 2026: Trial started

NCT07502560: A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

State
Under way
Phase
Phase 4
People
33,609 planned
Started
31 Mar 2026
Primary completion
1 Apr 2030
Arms
Recombinant zoster vaccine Group
Results
None posted
  1. 31 Mar 2026: Trial registered
  2. 31 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as RZV vaccine, Recombinant Herpes Zoster Vaccine (Shingrix), Recombinant zoster vaccine, Shingrix.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.